Bacteriophage-host interaction: From splendid isolation into a messy reality

Current Opinion in Microbiology

Volumn 16, Issue 4, 2013, Pages 500-506

  Brüssow, Harald ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGE RECEPTOR; EXTRACELLULAR POLYSACCHARIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIOPHAGE; BACTERIOPHAGE HOST INTERACTION; BACTERIOPHAGE T4; BACTERIOPHAGE T7; BACTERIUM ADHERENCE; BACTERIUM COLONY; BIOFILM; CATHETER INFECTION; CYSTIC FIBROSIS; ENDOCARDITIS; HOST PATHOGEN INTERACTION; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; NONHUMAN; NUTRIENT LIMITATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; URINARY CATHETER;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

ANIMALS; BIOFILMS; BIOLOGICAL THERAPY; ECOSYSTEM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GASTROINTESTINAL TRACT; HUMANS; T-PHAGES;

EID: 84882832884     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.04.007     Document Type: Review

References (52)

1. Twort F.W. An investigation on the nature of ultra-microscopic viruses. Lancet 1915, 2:1241-1243.
2. D'Herelle F. Sur un microbe invisible antagoniste des bacteries dysentériques. C R Acad Sci Paris 1917, 165:373-375.
3. Häusler T. Viruses vs. Superbugs: A Solution to the Antibiotics Crisis 2007, Palgrave Macmillan, London.
4. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45:649-659.
5. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
6. Brock T.D. The Emergence of Bacterial Genetics 1990, CSHL Press, New York, USA.
7. Cairns J., Stent G.S., Watson J.D. Phage and the Origins of Molecular Biology 1966, CSHL of Quantitative Biology, New York, USA.
8. Fuhrman J.A. Marine viruses and their biogeochemical and ecological effects. Nature 1999, 399:541-548.
9. Wommack K.E., Colwell R.R. Virioplankton: viruses in aquatic ecosystems. Microbiol Mol Biol Rev 2000, 64:69-114.
10. Filée J., Tétart F., Suttle C.A., Krisch H.M. Marine T4-type bacteriophages, a ubiquitous component of the dark matter of the biosphere. Proc Natl Acad Sci U S A 2005, 102:12471-12476.
11. Reyes A., Semenkovich N.P., Whiteson K., Rohwer F., Gordon J.I. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol 2012, 10:607-617.
12. Chibani-Chennoufi S., Sidoti J., Bruttin A., Dillmann M.L., Kutter E., Qadri F., Sarker S.A., Brüssow H. Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol 2004, 186:8287-8294.
13. Weiss M., Denou E., Bruttin A., Serra-Moreno R., Dillmann M.L., Brüssow H. In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology 2009, 393:16-23.
14. Maura D., Galtier M., Le Bouguénec C., Debarbieux L. Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob Agents Chemother 2012, 56:6235-6242.
15. Maura D., Morello E., du Merle L., Bomme P., Le Bouguénec C., Debarbieux L. Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environ Microbiol 2012, 14:1844-1854.
16. Mahichi F., Synnott A.J., Yamamichi K., Osada T., Tanji Y. Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett 2009, 295:211-217.
17. Sarker S.A., McCallin S., Barretto C., Berger B., Pittet A.C., Sultana S., Krause L., Huq S., Bibiloni R., Bruttin A., Reuteler G., Brüssow H. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012, 434:222-232.
18. Luria S.E., Delbrück M. Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics 1943, 28:491-511.
19. Weitz J.S., Hartman H., Levin S.A. Coevolutionary arms races between bacteria and bacteriophage. Proc Natl Acad Sci U S A 2005, 102:9535-9540.
20. Trojet S.N., Caumont-Sarcos A., Perrody E., Comeau A.M., Krisch H.M. The gp38 adhesins of the T4 superfamily: a complex modular determinant of the phage's host specificity. Genome Biol Evol 2011, 3:674-686.
21. Flores C.O., Meyer J.R., Valverde S., Farr L., Weitz J.S. Statistical structure of host-phage interactions. Proc Natl Acad Sci U S A 2011, 108:E288-E297.
22. Heilmann S., Sneppen K., Krishna S. Coexistence of phage and bacteria on the boundary of self-organized refuges. Proc Natl Acad Sci U S A 2012, 109:12828-12833.
23. Fey P.D. Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections?. Curr Opin Microbiol 2010, 13:610-615.
24. Gander S. Bacterial biofilms: resistance to antimicrobial agents. J Antimicrob Chemother 1996, 37:1047-1050.
25. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001, 45:999-1007.
26. Smith H.W., Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128:307-318.
27. Smith H.W., Huggins M.B. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983, 129:2659-2675.
28. Smith H.W., Huggins M.B., Shaw K.M. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987, 133:1111-1126.
29. Francis T., Terrell E.E., Dubos R., Avery O.T. Experimental type III pneumococcus pneumonia in monkeys. II. Treatment with an enzyme which decomposes the specific capsular polysaccharide of pneumococcus type III. J Exp Med 1934, 59:641-667.
30. Scholl D., Adhya S., Merril C. Escherichia coli K1's capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 2005, 71:4872-4874.
31. Scholl D., Rogers S., Adhya S., Merril C.R. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J Virol 2001, 75:2509-2515.
32. Cornelissen A., Ceyssens P.J., T'Syen J., Van Praet H., Noben J.P., Shaburova O.V., Krylov V.N., Volckaert G., Lavigne R. The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties. PLoS ONE 2011, 6:e18597.
33. Cornelissen A., Ceyssens P.J., Krylov V.N., Noben J.P., Volckaert G., Lavigne R. Identification of EPS-degrading activity within the tail spikes of the novel Pseudomonas putida phage AF. Virology 2012, 434:251-256.
34. Hu J., Miyanaga K., Tanji Y. Diffusion of bacteriophages through artificial biofilm models. Biotechnol Prog 2012, 28:319-326.
35. Doolittle M.M., Cooney J.J., Caldwell D.E. Lytic infection of Escherichia coli biofilms by bacteriophage T4. Can J Microbiol 1995, 41:12-18.
36. Doolittle M.M., Cooney J.J., Caldwell D.E. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Ind Microbiol 1996, 16:331-341.
37. Lu T.K., Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 2007, 104:11197-11202.
38. Donlan R.M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 2009, 17:66-72.
39. Curtin J.J., Donlan R.M. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006, 50:1268-1275.
40. Fu W., Forster T., Mayer O., Curtin J.J., Lehman S.M., Donlan R.M. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 2010, 54:397-404.
41. Liao K.S., Lehman S.M., Tweardy D.J., Donlan R.M., Trautner B.W. Bacteriophages are synergistic with bacterial interference for the prevention of Pseudomonas aeruginosa biofilm formation on urinary catheters. J Appl Microbiol 2012, 113:1530-1539.
42. Verma V., Harjai K., Chhibber S. Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. J Antimicrob Chemother 2009, 64:1212-1218.
43. Alemayehu D., Casey P.G., McAuliffe O., Guinane C.M., Martin J.G., Shanahan F., Coffey A., Ross R.P., Hill C. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012, 3:e00029-12.
44. Krogfelt K.A., Poulsen L.K., Molin S. Identification of coccoid Escherichia coli BJ4 cells in the large intestine of streptomycin-treated mice. Infect Immun 1993, 61:5029-5034.
45. Poulsen L.K., Licht T.R., Rang C., Krogfelt K.A., Molin S. Physiological state of Escherichia coli BJ4 growing in the large intestines of streptomycin-treated mice. J Bacteriol 1995, 177:5840-5845.
46. Freter R., Stauffer E., Cleven D., Holdeman L.V., Moore W.E. Continuous-flow cultures as in vitro models of the ecology of large intestinal flora. Infect Immun 1983, 39:666-675.
47. Rang C.U., Licht T.R., Midtvedt T., Conway P.L., Chao L., Krogfelt K.A., Cohen P.S., Molin S. Estimation of growth rates of Escherichia coli BJ4 in streptomycin-treated and previously germfree mice by in situ rRNA hybridization. Clin Diagn Lab Immunol 1999, 6:434-436.
48. Woods D.R. Bacteriophage growth on stationary phase Achromobacter cells. J Gen Virol 1976, 32:45-50.
49. Wiggins B.A., Alexander M. Minimum bacterial density for bacteriophage replication: implications for significance of bacteriophages in natural ecosystems. Appl Environ Microbiol 1985, 49:19-23.
50. Barletta F., Ochoa T.J., Mercado E., Ruiz J., Ecker L., Lopez G., Mispireta M., Gil A.I., Lanata C.F., Cleary T.G. Quantitative real-time polymerase chain reaction for enteropathogenic Escherichia coli: a tool for investigation of asymptomatic versus symptomatic infections. Clin Infect Dis 2011, 53:1223-1229.
51. Merabishvili M., Pirnay J.P., Verbeken G., Chanishvili N., Tediashvili M., Lashkhi N., Glonti T., Krylov V., Mast J., Van Parys L., Lavigne R., Volckaert G., Mattheus W., Verween G., De Corte P., Rose T., Jennes S., Zizi M., De Vos D., Vaneechoutte M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 2009, 4:e4944.
52. Kwan T., Liu J., DuBow M., Gros P., Pelletier J. The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci U S A 2005, 102:5174-5179.